Home | Back to newsletter main page
 |
|
December 13, 2010 |
|
MESSAGE FROM THE DIRECTORPhilip H. Howe, PhD Appointed Case CCC Associate Director for Basic Research at the LRI
Phil is an active investigator in cancer signaling including TGF–beta, Wnt, FoxO3 and related pathways. He is organizing a TGF–beta multi investigator effort. Please contact Phil for strategic advice if you plan to form a multi–investigator working group. The Cancer Center will support these activities, with assistance for meetings, collaborations and grant applications. Likewise, with these initiatives, Phil will recommend areas for investment to the Cancer Center Senior Leaders and will assist in developing RFAs for focused research ideas. Please join me in congratulating Phil and, when he calls on you, offer your enthusiastic support and creative ideas for cutting edge cancer research. He and I are available to meet with members any time. Thank you for your commitment to cancer research at the Case Comprehensive Cancer Center. Stan Gerson, MD Click here to read the full announcement. CASE CCC IN THE NEWSCancer Doctors Urge Caution Over Taking Daily Aspirin CWRU News Center Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health (NIH), in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors. Researchers Mark Chance, PhD, professor of physiology and biophysics, director of the Center for Proteomics and Bioinformatics, and interim chair of the Department of Genetics, and W. Henry Boom, MD, professor of medicine and director of the Tuberculosis Research Unit, are working to tackle the easily transmissible, and often deadly, Mycobacterium tuberculosis (MTB)... The Case Comprehensive Cancer Center was awarded a new $2.5 million grant from the National Cancer Institute (NCI) to evaluate the introduction and expression of the modified MGMT gene in hematopoietic stem cells in an effort to improve efficacy of chemotherapy for glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain tumor in humans... This trial will build on the more than two decades of research by Stanton Gerson, MD, principal investigator of the study, the Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology, and director of the NCI-designated Case Comprehensive Cancer Center. .. In another example of a team science approach, members of the Case Comprehensive Cancer Center have been tapped to join an important NCI multisite prospective study of all grade II, III and IV glioma patients within the state... researchers will be part of The Cancer Genome Atlas (TCGA) Project, which is a national comprehensive and coordinated effort to accelerate understanding of the genetics of cancer using innovative genome analysis technologies... Under the direction of principal investigator Jill Barnholtz-Sloan, PhD, assistant professor of general medical sciences, newly diagnosed patients with gliomas will be prospectively accrued from her Ohio Brain Tumor Study (OBTS), a multisite study within Ohio... Case Western Reserve faculty have worked closely with TCGA for many years; Barnholtz-Sloan and Andrew Sloan, MD, the Peter D. Cristal Chair in Neurosurgery at the School of Medicine and director of the Brain Tumor and Neuro-Oncology Center at UHCMC are active members of the TCGA Glioma Disease Expert Working groups... In addition, Neal Meropol, MD, Chief, Division of Hematology and Oncology, Case Western Reserve University School of Medicine and UH Case Medical Center and Associate Director for Clinical Research, Case Comprehensive Cancer Center, is a member of the TCGA Colorectal Cancer Disease Expert Working group. The Department of Bioethics was awarded a $2.5 million continuation grant from the National Human Genome Research Institute that will extend funding for its Center for Genetic Research Ethics and Law (CGREAL) for an additional four years... It is co-directed through the collaborative partnership of Patricia Marshall, PhD, professor of bioethics, and Richard Sharp, PhD, director of research in the Department of Bioethics at the Cleveland Clinic. The mission of the CGREAL is to conduct transdisciplinary studies of ethical and societal issues in human genetic research and the introduction of new genetic technologies into patient care and public health; additionally it seeks to prepare young scholars for successful careers in Ethical, Legal, Social Issues (ELSI) research... ANNOUNCEMENTSBasic, Clinical, or Translational Human Tissue Based Cancer Research Project AwardsThe Case Comprehensive Cancer Center is pleased to announce the recipients of pilot funding to support basic, clinical or translational human tissue based research. The purpose of these awards is to foster collaborations and to promote and increase institution-wide capacity and competitiveness in research. James Jacobberger, PhD: Cell Signaling as an Acute Myeloid Leukemia Biomarker Ruth Keri, PhD: Follistatin as an Inhibitor of Metastatic Progression in Breast Cancer Andrew Sloan, MD: Targeted Proteomics to Predict Differential Glioblastoma Survival Jill Barnholtz-Sloan, PhD: Development of Human Brain Tumor Tissue Microarrays Ge Jin, PhD: Human β–defensins as Novel Biomarkers for Precancerous Lesions of Colorectal Cancer Cheryl Thompson, PhD: A Biorepository for Research in Lung Cancer Risk, Detection and Prognosis William Schiemann, PhD Oncogenic TGF–β Effectors are Novel Biomarkers for Recurrent Cancer |
EVENTS
**All events are open to anyone interested in attending December 13December 14Cancer Biology Invited Speaker Seminar Immunology Seminar Oncomine Workshop December 15Hematology and Oncology Division Research Conference Immunology Invited Speaker Seminar Series Developmental Therapeutics Program Meeting December 16December 17Special Seminar Taussig Cancer Institute Grand Rounds Cancer Center Seminar Series Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTSADDITIONAL UPCOMING SEMINARS & EVENTSActive Living Research Annual Conference Multilevel Interventions in Health Care: Building the Foundation for Future Research Goals 4th Annual Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science Call for Abstracts: 2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting Cancer Health Disparities Summit 2011 |
NCI Website on Transforming the NCI Clinical Trials EnterpriseThe Institute of Medicine (IOM) issued a report in April 2010 about reinvigorating the NCI Cooperative Group Program. The NCI met with the Chairs for the US Cooperative Groups that conduct clinical trials on November 29 in Bethesda, MD, to begin to discuss the issues raised by the IOM as well as other stakeholders in the NCI Clinical Trials Enterprise. The NCI has now launched a website to address general issues about transforming the Clinical Trials Enterprise and to begin the process of collecting data/input on these issues more specifically with various stakeholders over the next six months. The website can be accessed at: http://transformingtrials.cancer.gov/. The link to the information on transforming the program is listed under NCI's Clinical Trials Cooperative Group Program: Infrastructure in Transition. NCI will be making updates to the website as we move forward with this process. In the interim, if you have any questions or concerns, please contact: Meg Mooney, MD, Chief, NCI Clinical Investigations Branch at mooneym@ctep.nci.nih.gov. FUNDING OPPORTUNITIESACS Joseph S. Silber Student Research FellowshipThe American Cancer Society East Central Division, Ohio, offers the Joseph S. Silber Student Research Fellowship to undergraduate and graduate science majors and first-year medical students to encourage their participation in a sponsor's team-oriented project in cancer research at a Cleveland-area institution. The purpose is to expose students early in their careers to the problem of cancer in hopes that cancer research will become a lifelong interest and and pursuit. Deadline: January 28, 2011 |
MARK YOUR CALENDARSSecond Oncomine WorkshopThe Second Oncomine workshop will occur on Tuesday December 14 from 2-3 pm in SOM E324. To derive any benefit from the workshop, you must be registered with www.oncomine.org. We will revisit the basics covered in the first workshop, and extend ourselves a little further. Don't miss this opportunity to learn how to make your next grant proposal look better. Places are limited contact Patrick.Leahy@case.edu to reserve your spot. Cancer Imaging Nanotechnology Sub-group MeetingDrs. Jim Basilion and Zhenghong Lee would like to extend an invitation to the Case Comprehensive Cancer Imaging Program members to attend the next meeting of the Cancer Imaging Nanotechnology Sub-Group. The meeting will take place January 10 from 4-5 pm in the CCIR Conference Room, Wearn B-37. Please contact Marianne Sperk with any questions. |
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES |
|
|
AACR Basic Cancer Research Fellowships |
SU2C Innovative Research Grants |
NIH BULLETIN – Notices and Funding OpportunitiesPre-Solicitation Announcement: The Lasker Clinical Research Scholars Program (NOT-OD-11-030) Advanced In Vivo Imaging to Understand Cancer Systems (R01) (RFA-CA-11-005) Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R01) (PA-11-073) Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21) (PA-11-074) |
|
| Produced by: Gillian Irwin Todd 11100 Euclid Avenue, Wearn 149 Cleveland, Ohio 44106-5065 216-844-8317 phone 216-844-7832 fax gillian.irwin@case.edu |
HELP US HELP YOU!If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to gillian.irwin@case.edu. |
|
|
The Case CCC announces the appointment of